Ocean Biomedical Files 2024 Annual Report Amendment

Ticker: OCEA · Form: 10-K/A · Filed: Apr 29, 2025 · CIK: 1869974

Sentiment: neutral

Topics: amendment, annual-report, pharmaceuticals

TL;DR

Ocean Biomedical filed its amended 2024 10-K. Check financials.

AI Summary

Ocean Biomedical, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, previously known as Aesther Healthcare Acquisition Corp., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its business and mailing address are located at 515 Madison Ave, Suite 8078, New York, NY 10022.

Why It Matters

This filing provides updated information for investors regarding Ocean Biomedical's financial performance and business operations for the fiscal year 2024.

Risk Assessment

Risk Level: low — This is a routine amendment to an annual report, not indicating new or elevated risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 10-K/A filing?

This is Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2024, indicating updates or corrections to the original filing.

When was the original 10-K filed or when is this amendment effective?

The filing date for this amendment is April 29, 2025, and it pertains to the fiscal year ended December 31, 2024.

What was Ocean Biomedical, Inc. previously known as?

Ocean Biomedical, Inc. was formerly known as Aesther Healthcare Acquisition Corp. until a name change on February 14, 2023.

Where is Ocean Biomedical, Inc. located?

The company's business and mailing address is 515 Madison Ave, Suite 8078, New York, NY 10022.

What industry does Ocean Biomedical, Inc. operate in?

Ocean Biomedical, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.

Filing Details

This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 29, 2025 regarding Ocean Biomedical, Inc. (OCEA).

View full filing on EDGAR

View Full Filing

View this 10-K/A filing on SEC EDGAR

View on Read The Filing